Sector News

Ex-Moderna CSO resurfaces at PureTech

October 21, 2016
Life sciences

The departure of Joseph Bolen from Moderna Therapeutics as its CSO last year, as well as other subsequent high-profile exoduses, has caused much speculation about the health of this ambitious biotech unicorn.

Now, Bolen is back as the CSO of PureTech Health, a venture firm that has since morphed a bit over the years into a publicly listed therapeutic discovery and development company.

There, he will lead the work on PureTech’s pipeline, which focuses on immune, nervous and gastrointestinal systems and includes more than 20 ongoing clinical trials. PureTech has 5 candidates that are in proof-of-concept studies, as well as multiple pivotal data readouts in the next couple of years.

“PureTech Health is one of the most exciting companies in biotech, advancing truly unique multi-modal solutions to some of today’s most significant healthcare challenges through modulation of the human nervous and immune adaptive systems,” Bolen said in a statement. “Our mission at PureTech Health is to collaborate broadly with biomedical science and technology leaders in order to generate the most exciting ideas and then to transform these concepts into breakthrough medicines.”

In this new role, Dr. Bolen will lead the scientific development and advancement of PureTech’s pipeline and will work closely with the team and Scientific Advisory Board as the company identifies and pursues new modalities to address significant medical needs.

Bolen held the position of CSO with Moderna for only 10 months, departing in October 2015. He started out at the Cambridge, MA-based company as its president of R&D; he held that spot for a little over a year and a half. Prior to that, he had been the CSO at Millennium Pharmaceuticals for 14 years. Millennium was acquired by Takeda in 2008 for $8.8 billion.

“Joe is a seasoned industry expert who brings the ideal balance of rigor and creativity to the role of CSO, and shares our vision for identifying and nurturing innovation that can potentially redefine healthcare,” said PureTech CEO Daphne Zohar.

By Stacy Lawrence

Source: Fierce Biotech

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.